Bayer and Evotec to collaborate on precision cardiology
Betsy Goodfellow | April 30, 2024 | News story | Research and Development | Bayer, Cardiology, cardio, cvd
Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of innovative precision treatments for cardiovascular diseases (CVDs).
The two companies intend to ‘identify and validate novel targets, with the goal of building a portfolio of precision cardiology therapeutics by leveraging Evotec’s disease modelling capabilities using human induced pluripotent stem cells (iPSCs)’, according to the press release.
Both companies are expected to contribute drug targets as well as a comprehensive set of technology platforms for the development of potential treatment options.
Dr Christian Rommel, head of research and development at Bayer’s pharmaceuticals division, commented: “CVDs are the leading cause of death globally. The refocused collaboration will leverage Evotec’s industrialised iPSC-based disease modelling platform and Bayer’s leadership in cardiology to advance a portfolio of innovative therapies for cardiovascular diseases with high unmet medical need. This complements our focus on disease areas where we can truly improve the standard of care by delivering superior therapeutic solutions to patients in need.”
Dr Cord Dohrmann, chief scientific officer at Evotec, added: “In order to move the treatment paradigm beyond disease management, it is important to advance our understanding of the disease-relevant molecular mechanisms underlying CVDs. Our approach is based on highly validated disease models to identify novel targets and profile drug candidates more comprehensively for their efficacy and safety. Intervening with these disease-associated mechanisms more comprehensively will enable the development of more effective, disease modifying therapies with higher relevance for CVD to respond to the substantial unmet need associated with cardiovascular diseases.”
Betsy Goodfellow
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Study finds new test could better predict risk of heart disease
A study by Harvard University, US, and Chalmers University of Technology, Sweden, has found that …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …
